Hepatocyte nuclear factor-1α is a causal factor responsible for interindividual differences in the expression of UDP-glucuronosyltransferase 2B7 mRNA in human livers

被引:32
作者
Toide, K
Takahashi, Y
Yamazaki, H
Terauchi, Y
Fujii, T
Parkinson, A
Kamataki, T
机构
[1] Hokkaido Univ, Grad Sch Pharmaceut Sci, Lab Drug Metab, Kita Ku, Sapporo, Hokkaido 0600812, Japan
[2] Dainippon Pharmaceut Co Ltd, Dept Pharmacokinet, Osaka, Japan
[3] Univ Kansas, Med Ctr, Ctr Environm & Occupat Hlth, Kansas City, KS 66103 USA
关键词
D O I
10.1124/dmd.30.6.613
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
UDP-glucuronosyltransferase (UGT) 2B7 is one of the most important UGT isozymes expressed in human livers. This enzyme is reported to show more than 10-fold interindividual differences in its enzyme activities. Thus, the amounts of UGT2B7 mRNA in 12 human livers were quantified by quantitative reverse transcription-polymerase chain reaction. The amounts of UGT2B7 mRNA in the subjects ranged from 0.22 to 2.63 copies/10(3) copies of beta-actin. A novel point mutation (-253G to A) found in this study did not affect the level of UGT2B7 mRNA in the subjects. To clarify a causal factor(s) determining the expression level of UGT2B7 mRNA, we examined the correlation between the amounts of mRNAs for UGT2B7 and hepatocyte nuclear factor (HNF)-1alpha, which regulates the expression of UGT2B7 gene. HNF-1alpha mRNA was expressed at a level ranging from 2.99 to 24.76 copies/10(6) copies of beta-actin in the subjects. The amounts of mRNAs for UGT2B7 expressed in these individual liver samples were highly associated with the amount of mRNA for HNF-1alpha(r=0.786, p=0.002), suggesting that HNF-1alpha is a factor limiting the expression of UGT2B7 mRNA and a causal factor responsible for an interindividual difference in human livers.
引用
收藏
页码:613 / 615
页数:3
相关论文
共 23 条
[1]  
Barbier O, 2000, DRUG METAB DISPOS, V28, P497
[2]   Activation of the mouse TATA-less and human TATA-containing UDP-glucuronosyltransferase 1A1 promoters by hepatocyte nuclear factor 1 [J].
Bernard, P ;
Goudonnet, H ;
Artur, Y ;
Desvergne, B ;
Wahli, W .
MOLECULAR PHARMACOLOGY, 1999, 56 (03) :526-536
[3]  
BOSMA PJ, 1994, J BIOL CHEM, V269, P17960
[4]   Drug-mediated toxicity caused by genetic deficiency of UDP-glucuronosyltransferases [J].
Burchell, B ;
Soars, M ;
Monaghan, G ;
Cassidy, A ;
Smith, D ;
Ethell, B .
TOXICOLOGY LETTERS, 2000, 112 :333-340
[5]   Normalization and subtraction of cap-trapper-selected cDNAs to prepare full-length cDNA libraries for rapid discovery of new genes [J].
Carninci, P ;
Shibata, Y ;
Hayatsu, N ;
Sugahara, Y ;
Shibata, K ;
Itoh, M ;
Konno, H ;
Okazaki, Y ;
Muramatsu, M ;
Hayashizaki, Y .
GENOME RESEARCH, 2000, 10 (10) :1617-1630
[6]  
Coffman BL, 1998, DRUG METAB DISPOS, V26, P73
[7]  
Furlan V, 1999, J PHARMACOL EXP THER, V289, P1169
[8]   Tissue specific differences in the regulation of the UDP glucuronosyltransferase 2B17 gene promoter [J].
Gregory, PA ;
Hansen, AJ ;
Mackenzie, PI .
PHARMACOGENETICS, 2000, 10 (09) :809-820
[9]   HNF1 alpha activates the rat UDP glucuronosyltransferase UGT2B1 gene promoter [J].
Hansen, AJ ;
Lee, YH ;
Gonzalez, FJ ;
Mackenzie, PI .
DNA AND CELL BIOLOGY, 1997, 16 (02) :207-214
[10]  
Ishii Y, 2000, MOL PHARMACOL, V57, P940